Aurobindo Pharma reported a fire incident on September 18, 2025, at its APL Healthcare Unit-IV in Andhra Pradesh due to a short circuit, ca...

The stock with a market capitalisation of more than Rs 8,500 crore hit a 52 week-high of Rs 362

Rao has over two decades of experience in pharmaceutical and chemical industries.

Granules has received marketing approval from the US Food and Drug Administration (USFDA) for Potassium Chloride extended release tablets U...

Brokerage sees coronavirus crisis as a positive for companies like Granules India and Natco.

SA Ajinomoto Omnichem NV will take over full control of the contract research and manufacturing services (CRAMS) business, said Granules In...

As per the USFDA, a Form 483, is issued to a firm's management at the conclusion of an inspection when investigator has observed any condit...

Granules Pharmaceuticals Inc, a wholly-owned foreign subsidiary of the company completed its first audit from December 4-8, 2017 by the USF...

Granules said it will be responsible for the marketing and distribution of the products in the US, subject to the final approval by the US ...

Granules India has received Establishment Inspection Report from the US health regulator for the inspection done at the company's Jeedimetl...

More analysts are getting attracted to this counter because the recent correction has brought down its valuations to reasonably levels.

Ajanta Pharma today said it has launched generic version of Singulair granules, used in the treatment of asthma, in the US market.

Drug firm Ajanta Pharma has received final approvals from the US health regulator for generic montelukast tablets and oral granules.

"Some stocks that immediately come to my mind are Sundram Fasteners and Igarashi Motors ... These two stocks, along with others, can return...

Hyderabad-based pharmaceutical firm Granules India has agreed to buy Auctus Pharma for about Rs 100 crore in an all-cash deal.

The acquisition process is expected to be completed in the next 3 to 6 months, a release from Hyderabad-based Granules India said.

Hyderabad-based pharma firm Granules India is close to finalising a Rs 180-200-crore deal with a Chinese pharmaceutical company.